hydroxyurea (Hydrea, Droxia) Uses, Side Effects & Dosage

What is hydroxyurea, and how does it work (mechanism of action)?

Hydroxyurea (Hydrea) is an oral medication used to
treat several types of cancers including chronic myelogenous leukemia (CML),
acute myelogenous leukemia (AML), head and neck cancer,
malignant melanoma,
ovarian cancer, and polycythemia vera (a disorder of the bone marrow). The exact
mechanism by which hydroxyurea works to treat cancer is not understood. However,
it is thought that hydroxyurea causes an immediate inhibition of DNA synthesis
by inhibiting an enzyme called ribonucleotide reductase. Interrupting DNA
synthesis reduces the growth of cancer cells.

In-addition to treating cancer, Droxia another oral form of hydroxyurea is
used in the management of sickle cell disease. The exact mechanism by which
hydroxyurea works to treat sickle cell disease is not understood. The FDA
approved hydroxyurea in December 1967.

What brand names are available for hydroxyurea?

Hydrea, Droxia

Is hydroxyurea available as a generic drug?

Yes

Do I need a prescription for hydroxyurea?

Yes

What are the side effects of hydroxyurea?

Known side effects include:

• bone marrow suppression (drop in
  white blood cell, red blood cell and platelet counts),
• anorexia,
• nausea,
• vomiting,
• diarrhea,
• constipation,
• sores in the mouth,
• skin
  rash,
• swelling in the
  hands, feet, legs and face,
• changes in skin pigmentation,
• hair loss,
• painful
  urination,
• drowsiness,
• headache,
• dizziness,
• disorientation,
• hallucinations,
• seizures,
• liver problems,
• shortness of breath,
• metabolic disturbances, and
• kidney problems. 

What is the dosage for hydroxyurea?

For treating cancer: Dose should be titrated based on individual
patient response. Capsules should be swallowed whole. Hydroxyurea capsules
should be handled with extreme care and disposed of properly because it causes
cell damage.

For the treatment of solid tumors

• Intermittent therapy: 80 mg/kg administered
  orally as single dose every third day
• Continuous therapy: 20 to 30 mg/kg
  administered orally as a single daily dose
• Concomitant therapy with irradiation: Cancer
  of the head and neck, administer 80 mg/kg orally as a single dose every third
  day

For the treatment of chronic myelocytic leukemia

20 to 30 mg/kg administered
orally as a single daily dose is recommended.

As hydroxyurea is mainly eliminated from the body via the kidneys, dose
reductions may be necessary in patients with reduced kidney function.

For the treatment of sickle cell disease

Adults: administer 15 mg/kg by mouth once daily. Dose adjustments are made
based on patient’s blood counts. Patient’s blood counts are monitored every two
weeks. If the blood counts are in an "acceptable" range, the dose may be
increased by 5 mg/kg/day every 12 weeks until a maximum tolerated dose (highest
dose that does not produce toxic blood counts) or 35 mg/kg/day is reached.

Latest Cancer News

• Pandemic Delays in Screening, More Cancer Deaths
• Cancer Survivors Fared Better Financially
• Alcohol Tied to 740,000 Cancer Cases Worldwide
• Obese Men With Advanced Prostate Cancer
• Most Cancer Screenings Make Big Rebound
• Want More News? Sign Up for MedicineNet Newsletters!

Daily Health News

• H5N6 Bird Flu Infection in China
• COVID Vaccine Misinformation
• Antibiotic-Resistant Pneumonia
• Mask Mandate Returns to L.A.
• Fermented Foods Help Microbiome
• More Health News »

Trending on MedicineNet

• Guillain-Barre Syndrome
• What Triggers Shingles?
• Normal Blood Sugar Levels
• Identify Tick Bites
• Why Is Autism Increasing?

Learn More on

Which drugs or supplements interact with hydroxyurea?

:

Generally, use of live vaccines is contraindicated during treatment with
cancer drugs because cancer drugs weaken the immune system. People with weakened
immune systems have a decreased response to vaccines.

Hydroxyurea may cause a drop in platelet counts, an important type of blood
cells required for forming blood clots. Use of hydroxyurea with anticoagulants,
nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelets, and thrombolytic
agents increases the risk of bleeding.

Antineoplastic agents exert their benefits by killing rapidly growing cancer
cells. Use of medications that stimulate cell growth is usually not recommended
in patients who have been exposed to cytotoxic chemotherapy within 24 hours.
Specifically, the manufacturer of pegfilgrastim (Neulasta) recommends that
pegfilgrastim should not be administered to patients who have been treated with
cytotoxic chemotherapy within the prior 14 days. Also, chemotherapy should not
be administered within 24 hours of pegfilgrastim.

Hydroxyurea may increase blood uric acid concentration. Although no specific
dose adjustments are necessary with
probenecid or sulfinpyrazone (Anturane),
hydroxyurea should be used cautiously with uricosuric medications.

Use of hydroxyurea with didanosine (Videx, Videx EC), with or without
stavudine (Zerit, Zerit XR), has been associated with an increased incidence of
side effects including pancreatitis and peripheral neuropathy (nerve problems).
In general, hydroxyurea is not recommended in HIV patients as decreased CD4
counts, decreased viral suppression, and increased risk of side effects has been
reported.

Is hydroxyurea safe to take if I’m pregnant or breastfeeding?

Hydroxyurea can cause harm to the unborn baby and therefore,
should not be used during pregnancy. Although there are no adequate and
well-controlled studies in pregnant women, in animals studies hydroxyurea was
found to cause birth defects.

Hydroxyurea is secreted in human milk. Nursing should be stopped due to the potential for serious adverse reactions in the infant.

What else should I know about hydroxyurea?

What preparations of hydroxyurea are available?

• Hydrea: 500 mg capsules. Hydrea is used an antineoplastic agent.
• Droxia: 200 mg, 300 mg, 400 mg capsules. Droxia is used to treat sickle
  cell disease.

How should I keep hydroxyurea stored?

Capsules should be stored at room temperature between 59 F to 86 F
(15 C to 30 C).